Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind double-dummy active-controlled multicenter study of QLM1016 in schizophrenia
CTR20250315Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QLM1016 in schizophrenia, sponsored by Qilu Pharmaceutical. Started Oct 2025; status: active.
02
Drugs
QLM1016
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20250315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250315.